Reported 23 days ago
Craig-Hallum has reiterated a Buy rating for Clover Health Investments (CLOV), setting a price target of $6. The company reported a significant Q1 2025 performance, with a 30% increase in Medicare Advantage membership and a 33% growth in revenue to $462 million. Adjusted EBITDA surged 279%, while adjusted net income climbed 322%. Despite a GAAP net loss decreasing to $1 million, the company's operational improvements are notable.
Source: YAHOO